DYRK2 and plasma cell myeloma: Initially, we had thought that this pathway was specific primarily for TNBC and myeloma; however, this work shows that HSF1 and DYRK2 expressions correlate across cell states (Figure 1A–D) and therapy responses (Figure 1E,F) in diverse cancer types.